Return to homepagePandemic Pact

SPIKE-1 Trial; A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    LifeArc

  • Principal Investigator

    Unspecified Unspecified Unspecified

  • Research Location

    United Kingdom

  • Lead Research Institution

    The University of Edinburgh, Cancer Research UK, Latus Therapeutics Ltd

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Latus Therapeutics is leading a joint research team of scientists from University of Oxford and the University of Edinburgh to commence a clinical trial testing camostat in early COVID-19 disease in 390 patients in the community setting. The trial is managed by Cancer Research UK with funding from LifeArc. Camostat is a drug widely used in Japan to treat pancreatic diseases. It is a serine protease inhibitor that also inhibits the TPMRSS2 enzyme which plays an important role in enabling SARS-CoV-2 to infect healthy cells. Although not yet tested in humans with COVID-19, studies in SARS infected mice have shown that camostat treatment can prevent death.